Misoprostol: An essential medicine for managing postpartum hemorrhage in low-resource settings?

International Journal of Gynecology and Obstetrics

Volumn 114, Issue 3, 2011, Pages 209-210

  Rushwan, Hamid ^a  

^a FIGO House   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MISOPROSTOL; OXYTOCIN; PLACEBO; UTEROTONIC AGENT;

CAUSE OF DEATH; CHEMOPROPHYLAXIS; DRUG EFFICACY; DRUG SAFETY; EDITORIAL; HEALTH CARE DELIVERY; HEALTH CARE DISTRIBUTION; HUMAN; MATERNAL MORTALITY; POSTPARTUM HEMORRHAGE; PRIORITY JOURNAL;

EID: 79961168164     PISSN: 00207292     EISSN: 18793479     Source Type: Journal    
DOI: 10.1016/j.ijgo.2011.06.006     Document Type: Editorial

References (12)

1. WHO Maternal mortality Fact sheet No. 348 http://www.who.int/mediacentre/ factsheets/fs348/en/index.html Published November 2010
2. UNFPA State of World Population 2010. From conflict and crisis to renewal: generations of change http://www.unfpa.org/swp/2010/web/en/pdf/EN- SOWP10.pdf Published 2010
3. ICM, and FIGO Prevention and Treatment of Post-partum Haemorrhage. New Advances for Low Resource Settings http://www.pphprevention.org/files/FIGO-ICM- Statement-November2006-Final.pdf Published November 2006
4. Lalonde A. Safe Motherhood and Newborn Health Committee. FIGO Guidelines for the prevention and treatment of postpartum hemorrhage in low-resource settings. Int J Gynecol Obstet; in press.
5. N. Mobeen, J. Durocher, N. Zuberi, N. Jahan, J. Blum, and S. Wasim Administration of misoprostol by trained traditional birth attendants to prevent postpartum haemorrhage in homebirths in Pakistan: a randomised placebo-controlled trial BJOG 118 3 2011 353 361
6. R.J. Derman, B.S. Kodkany, S.S. Goudar, S.E. Geller, V.A. Naik, and M.B. Bellad Oral misoprostol in preventing postpartum haemorrhage in resource-poor communities: a randomised controlled trial Lancet 368 9543 2006 1248 1253 (Pubitemid 44485797)
7. B. Winikoff, R. Dabash, J. Durocher, E. Darwish, T.N. Nguyen, and W. León Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women not exposed to oxytocin during labour: a double-blind, randomised, non-inferiority trial Lancet 375 9710 2010 210 216
8. J. Blum, B. Winikoff, S. Raghavan, R. Dabash, M.C. Ramadan, and B. Dilbaz Treatment of post-partum haemorrhage with sublingual misoprostol versus oxytocin in women receiving prophylactic oxytocin: a double-blind, randomised, non-inferiority trial Lancet 375 9710 2010 217 223
9. S. Rajbhandari, S. Hodgins, H. Sanghvi, R. McPherson, Y.V. Pradhan, and A.H. Baqui Expanding uterotonic protection following childbirth through community-based distribution of misoprostol: operations research study in Nepal Int J Gynecol Obstet 108 3 2010 282 288
10. H. Sanghvi, N. Ansari, N.J. Prata, H. Gibson, A.T. Ehsan, and J.M. Smith Prevention of postpartum hemorrhage at home birth in Afghanistan Int J Gynecol Obstet 108 3 2010 276 281
11. WHO Unedited Report of the 18th Expert Committee on the Selection and Use of Essential Medicines, 21-25 March 2011, Accra, Ghana http://www.who.int/ selection-medicines/Complete-UNEDITED-TRS-18th.pdf Published May 2011
12. WHO WHO Statement regarding the use of misoprostol for postpartum haemorrhage prevention and treatment http://whqlibdoc.who.int/hq/2009/WHO-RHR- 09.22-eng.pdf Published 2009